Therapeutics case studies

A pharmaceutical sponsor launched a global trial for elderly UTI patients, opening 125 sites across 15 countries. Enrolment lagged at 1 patient per site per month, with 70% non-enrolling. ICON was brought in to rescue the study.

A virtual biotech start-up acquired an immunomodulatory mechanism targeting inflammatory pathways. It had undergone phase 1 and small phase 2a studies. With urgency to advance development and limited resources, the client proposed two separate studies, posing challenges in complexity, timeline, and budget. The client turned to ICON to streamline development.

Over 19 days, ICON conducted a focused site engagement programme to increase patient screening and accelerate enrolment of a late phase multinational, multicentre study to evaluate a treatment for pulmonary disease.

A sponsor conducting an international Phase III program of two double-blind, randomised studies consulted ICON’s respiratory experts for assistance in patient enrolment, and study planning and monitoring.

The client tasked ICON plc with managing six phase 3 clinical trials, with overlapping timelines, to further evaluate this
drug in patients with AD.

ICON provided a large pharma sponsor with consistent, accurate ECG and ECHO modality imaging, contributing to a breakthrough pulmonary arterial hypertension treatment.

A randomised, double-blind, placebo-controlled study on behalf of a biotechnology organisation to evaluate the safety, tolerability, and efficacy of the study drug in subjects with moderate to severe plaque psoriasis.

A Chinese sponsor adopts a blended delivery model to realise cost savings and assume greater autonomy.

A customised blended model has benefitted a top 10 pharma partner as their organisation has evolved over 13 years.